Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 1.00 |
| ▸ | MMP13 | P45452 | 3/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 0.79 |
| ▸ | MMP3 | P08254 | 2/20 | 0.77 |
| ▸ | IDH1 | O75874 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.67 |
| ▸ | MGAM | O43451 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | SI | P14410 | 1/20 | 0.67 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.67 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | NAT1 | P18440 | 1/20 | 0.64 |
| ▸ | CTSD | P07339 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249080 | 1.00 | ADAMTS5 (1.00) | ADAMTS5MMP13GSK3BMMP3IDH1 | |
| SCHEMBL12891797 | 1.00 | ADAMTS5 (1.00) | ADAMTS5MMP13GSK3BMMP3IDH1 | |
| SCHEMBL7968335 | 0.90 | ADAMTS5 (0.81) | ADAMTS5MMP13GSK3BMMP3IDH1 | |
| SCHEMBL7968336 | 0.90 | ADAMTS5 (0.81) | ADAMTS5MMP13GSK3BMMP3IDH1 | |
| SCHEMBL1248799 | 0.88 | CNR1 (0.81) | ADAMTS5MMP13MMP3MEN1KMT2A | |
| SCHEMBL1248797 | 0.88 | CNR1 (0.81) | ADAMTS5MMP13MMP3MEN1KMT2A | |
| SCHEMBL9433307 | 0.88 | CNR1 (0.81) | ADAMTS5MMP13MMP3MEN1KMT2A | |
| SCHEMBL7972192 | 0.87 | ADAMTS5 (0.77) | ADAMTS5MMP13GSK3BMMP3IDH1 | |
| SCHEMBL21538213 | 0.87 | ADAMTS5 (0.77) | ADAMTS5MMP13GSK3BMMP3IDH1 | |
| SCHEMBL20976496 | 0.87 | ADAMTS5 (0.77) | ADAMTS5MMP13GSK3BMMP3IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | claimed |
| US-9982309-B2 | Method for treating cell proliferation related disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9896421-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use thereof | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2018-02-20 | — | — | US | disclosed |
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | SERVIER PHARMACEUTICALS LLC | 2017-02-16 | — | — | US | disclosed |
| US-9434979-B2 | Methods and compositions for cell-proliferation-related disorders | SERVIER PHARMACEUTICALS LLC | 2016-09-06 | — | — | US | disclosed |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | disclosed |
| US-9216148-B2 | Compound having skin-whitening, anti-oxidizing and PPAR activities and medical use therefor | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2015-12-22 | — | — | US | disclosed |
| US-20150240286-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140187435-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-03 | — | — | US | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170325708-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | MKI67, BRCA1, CLN6 | ADAMTS5 1332/4885MMP13 1460/4885GSK3B 3263/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | ADAMTS5 3729/4885MMP13 3957/4885GSK3B 4545/4885 |
| US-20170044620-A1 | METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS | IDH2, IDH1, IDH3B | ADAMTS5 1629/4885MMP13 1044/4885GSK3B 1425/4885 |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | ADAMTS5 2030/4885MMP13 123/4885GSK3B 3223/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | ADAMTS5 3575/4885MMP13 3353/4885GSK3B 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.